产甲胎蛋白胃癌治疗及预后相关基因的研究进展  

Research Progress of Genes Related to Treatment and Prognosis of Alpha-fetoprotein Producing Gastric Cancer

作　　者：卢顺利 于建平 陈为凯 李安东 何清远 陈超 韩晓鹏 LU Shunli;YU Jianping;CHEN Weikai;LI Andong;HE Qingyuan;CHEN Chao;HAN Xiaopeng(The First Clinical Medicine College of Gansu University of Chinese Medicine,Lanzhou 730000,China;Department of General Surgery,940 Hospital of PLA Joint Logistics Support Force,Lanzhou 730050,China;Department of General Surgery,Gansu Central Hospital,Lanzhou 730070,China)

机构地区：[1]甘肃中医药大学第一临床医学院,兰州730000 [2]解放军联勤保障部队第940医院普外科,兰州730050 [3]甘肃省中心医院普外科,兰州730070

出　　处：《肿瘤防治研究》2022年第7期738-744,共7页Cancer Research on Prevention and Treatment

基　　金：甘肃省自然科学基金(20JR5RA599,21JR11RA172);甘肃省卫生健康行业科研项目(GSWSKY2021-015);甘肃省青年科技基金计划(21JR7RA013)。

摘　　要：产甲胎蛋白胃癌(AFPGC)是一种特殊类型的胃癌,被认为是具有高度侵袭性的肿瘤,其恶性程度高,且极易发生转移,以至于对其治疗效果不佳、预后差。目前,治疗的手段以及监测的指标对该病效果有限,而VEGF、HER2、AFP、GPC3、SALL4相关基因与肿瘤发生、发展有着密切关系,如能合理地指导AFPGC的治疗与预后,将大大改善患者生活质量,延长患者生存期。本文将对产甲胎蛋白胃癌治疗及预后相关基因的研究进展作一综述。Alpha-fetoprotein producing gastric cancer(AFPGC)is a special type of gastric cancer.AFPGC is considered to be the most highly invasive tumor with a high degree of malignancy and prone to metastasis.As a consequence,it usually causes unsatisfied treatment effect and the prognosis is poor.At present,treatment methods and monitoring indicators have limited effect on AFPGC.VEGF,HER2,AFP,GPC3 and SALL4 are cogently associated with tumor genesis and development.If we can reasonably guide the treatment and prognosis of AFPGC patients,it will greatly improve the situation of patients and improve the survival of patients.This article reviews the research progress of the genes related to the treatment and prognosis of AFPGC.

关 键 词：产甲胎蛋白胃癌 基因 分子机制 治疗 预后 

分 类 号：R735.2[医药卫生—肿瘤]